New treatments show progress against autoimmune and inflammatory conditions. Apogee Therapeutics' anti-IL-13 antibody demonstrated significant efficacy with a more convenient dosing schedule in phase 2 trials for atopic dermatitis. Cogent Biosciences’ bezuclastinib showed positive results in Phase 3 trials for systemic mastocytosis, targeting the KIT mutation. Additionally, a JAK inhibitor drug was found to prevent and reverse immunotherapy-induced diabetes in preclinical models, offering hope for managing immune checkpoint inhibitor side effects without impacting cancer treatment efficacy.